Fort Washington Investment Advisors INC Trimmed Its Bio (BIO) Holding as Market Valuation Rose

Bio-Rad Laboratories, Inc. (NYSE:BIO) LogoInvestors sentiment increased to 1.46 in 2019 Q1. Its up 0.45, from 1.01 in 2018Q4. It improved, as 29 investors sold BIO shares while 82 reduced holdings. 61 funds opened positions while 101 raised stakes. 17.40 million shares or 11.49% less from 19.66 million shares in 2018Q4 were reported. Amer Century Companies has invested 0.24% in Bio-Rad Laboratories, Inc. (NYSE:BIO). Proshare Ltd Limited Liability Company reported 0% in Bio-Rad Laboratories, Inc. (NYSE:BIO). The Ontario – Canada-based Cibc Mkts has invested 0% in Bio-Rad Laboratories, Inc. (NYSE:BIO). 41,913 were reported by Tygh Capital. Stewart & Patten Ltd Liability reported 0.12% of its portfolio in Bio-Rad Laboratories, Inc. (NYSE:BIO). Prudential Fincl Inc owns 12,254 shares. Citadel Advsrs Limited reported 0.01% of its portfolio in Bio-Rad Laboratories, Inc. (NYSE:BIO). Manufacturers Life Insur The has 135,493 shares for 0.04% of their portfolio. Twin Tree LP owns 27,058 shares for 0.04% of their portfolio. Advisor Prns Ltd Limited Liability Company invested in 0.03% or 845 shares. Charles Schwab Investment Mgmt owns 114,073 shares or 0.02% of their US portfolio. Employees Retirement Systems Of Texas reported 0.04% stake. Engineers Gate Manager LP invested in 0.09% or 5,125 shares. Virginia Retirement Sys Et Al has invested 0.01% in Bio-Rad Laboratories, Inc. (NYSE:BIO). Cibc Markets has 71,774 shares for 0.18% of their portfolio.

Fort Washington Investment Advisors Inc decreased its stake in Bio (BIO) by 12.73% based on its latest 2019Q1 regulatory filing with the SEC. Fort Washington Investment Advisors Inc sold 25,544 shares as the company’s stock rose 6.00% . The hedge fund held 175,158 shares of the capital goods company at the end of 2019Q1, valued at $53.54 million, down from 200,702 at the end of the previous reported quarter. Fort Washington Investment Advisors Inc who had been investing in Bio for a number of months, seems to be less bullish one the $9.51 billion market cap company. The stock increased 1.04% or $3.3 during the last trading session, reaching $319.13. About 170,094 shares traded. Bio-Rad Laboratories, Inc. (NYSE:BIO) has risen 3.54% since August 15, 2018 and is uptrending. It has outperformed by 3.54% the S&P500.

Fort Washington Investment Advisors Inc, which manages about $44.90B and $8.90 billion US Long portfolio, upped its stake in Verint Systems Inc (NASDAQ:VRNT) by 73,500 shares to 764,194 shares, valued at $45.75M in 2019Q1, according to the filing. It also increased its holding in Goldman Sachs Group Inc (NYSE:GS) by 32,067 shares in the quarter, for a total of 513,134 shares, and has risen its stake in Williams (NYSE:WSM).

More notable recent Bio-Rad Laboratories, Inc. (NYSE:BIO) news were published by: Finance.Yahoo.com which released: “See what the IHS Markit Score report has to say about Bio Rad Laboratories Inc. – Yahoo Finance” on May 07, 2019, also Seekingalpha.com with their article: “Bio-Rad Laboratories: More Growth Ahead – Seeking Alpha” published on July 10, 2019, Seekingalpha.com published: “Bio-Rad finance chief to retire – Seeking Alpha” on January 03, 2019. More interesting news about Bio-Rad Laboratories, Inc. (NYSE:BIO) were released by: Businesswire.com and their article: “Bio-Rad Receives U.S. FDA Clearance for the IH-500, Expanding Its Offering for the Blood Testing Market – Business Wire” published on April 08, 2019 as well as Seekingalpha.com‘s news article titled: “Bio-Rad Labs Q2 2019 Earnings Preview – Seeking Alpha” with publication date: July 31, 2019.

Bio-Rad Laboratories, Inc. (NYSE:BIO) Ratings Coverage

Among 2 analysts covering Bio-Rad Laboratories (NYSE:BIO), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Bio-Rad Laboratories has $350 highest and $34000 lowest target. $343.33’s average target is 7.58% above currents $319.13 stock price. Bio-Rad Laboratories had 6 analyst reports since February 23, 2019 according to SRatingsIntel. As per Friday, March 1, the company rating was maintained by Barclays Capital. The rating was maintained by Deutsche Bank on Friday, March 1 with “Buy”.

Bio-Rad Laboratories, Inc. (NYSE:BIO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.